According to Fortune Business Insights: The global non-invasive spinal cord stimulation (SCS) market was valued at USD 4.2 million in 2025 and is projected to grow from USD 7.9 million in 2026 to USD 66.5 million by 2034, exhibiting a remarkable CAGR of 30.4% during the forecast period. North America dominated the global market, holding the leading regional share in 2025 with a value of USD 4.0 million.
Non-invasive spinal cord stimulation is an emerging therapeutic modality that delivers electrical currents to the spinal cord via electrodes placed externally on the skin's surface over the spine — eliminating the need for surgical implantation. This approach enables stimulation of spinal neural circuits to improve mobility, hand and arm function, sensation, autonomic regulation, and overall neurological recovery in patients with spinal cord injuries and related conditions. The growing global burden of spinal cord injuries — with approximately 15 million people living with the condition worldwide, according to 2024 WHO data — and the rising preference for non-invasive treatment approaches are driving accelerating adoption of these devices across clinical and rehabilitation settings.
Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/117698
The defining trend shaping the market is a structural shift from traditional implantable neuromodulation toward external transcutaneous spinal cord stimulation for rehabilitation. Non-invasive SCS devices deliver stimulation through surface electrodes, enabling use in rehabilitation centers, neurorecovery programs, and increasingly home-based therapy — significantly broadening access compared to surgical implants. This trend is strongly supported by emerging clinical evidence. A 2024 Nature Medicine study involving 65 participants across 14 spinal cord injury (SCI) centers in the U.S., Europe, and Canada — the pivotal Up-LIFT study — demonstrated that non-invasive electrical stimulation of the cervical spinal cord, combined with structured rehabilitation, meaningfully improved hand and arm function in people with chronic tetraplegia due to spinal cord injury. This landmark evidence is accelerating the transition of non-invasive SCS from research settings into structured clinical rehabilitation pathways.
Growing Burden of Spinal Cord Injuries: The rising global incidence of spinal cord injuries is the primary market growth driver. In the U.S. alone, the annual incidence of SCI is approximately 54 cases per one million people, according to 2026 data from the Christopher & Dana Reeve Foundation. This sustained patient burden is generating growing demand for non-invasive rehabilitation technologies capable of improving mobility, upper-limb function, sensation, and quality of life without the risks, costs, and access barriers associated with surgical implantation.
Regulatory Approvals and Innovation: A growing number of product approvals from major regulatory bodies is fueling market confidence and commercial expansion. ONWARD Medical received U.S. FDA de novo classification for its ARC-EX System in December 2024, followed by its first U.S. commercial sales launch in January 2025 and expanded home-use authorization in November 2025. ANEUVO received CE Mark certification for its ExaStim transcutaneous spinal stimulation therapy in April 2025 and FDA approval in April 2026. These back-to-back regulatory milestones are catalyzing commercial market development globally.
Expanding Healthcare Infrastructure: Rapid healthcare infrastructure expansion in developing economies — including Brazil, India, and Southeast Asia — along with approximately 28,900 rehabilitation centers in the U.S., is broadening the institutional base for non-invasive SCS device adoption across hospitals, specialty clinics, and outpatient neurorehabilitation programs.
Limited Reimbursement Policies: The most significant growth restraint is the absence of standardized payer coverage pathways for non-invasive SCS therapy. Although the ARC-EX System has received regulatory approval for improving hand sensation and strength in chronic incomplete cervical spinal cord injury, reimbursement frameworks remain underdeveloped. This delays purchasing decisions by outpatient neurorehabilitation centers, rehabilitation hospitals, and homecare users. The total cost of therapy — encompassing the device, clinician time, training, rehabilitation sessions, and follow-up — compounds affordability challenges in the absence of insurance coverage.
Limited Healthcare Access in Developing Countries: A shortage of technologically advanced non-invasive SCS devices, limited healthcare expenditure, inadequate reimbursement structures, a limited number of specialist clinical facilities, and a shortage of trained professionals are collectively constraining adoption in emerging nations. The World Bank Group estimates that approximately 4.5 billion people globally lack full access to essential health services, underscoring the systemic barriers facing market expansion in lower-income regions.
By Product Type: The stimulation systems segment held the largest market share in 2025, driven by rising SCI prevalence and strong demand for complete non-invasive SCS platforms. The accessories segment is projected to grow at the fastest CAGR of 35.9% through 2034, reflecting the consumable and replacement electrode needs of an expanding installed device base.
By Technology: Transcutaneous electrical spinal cord stimulation (tSCS) overwhelmingly dominated the market with a 97.9% share in 2025, owing to strong clinical validation and regulatory approvals for this modality. The transspinal magnetic stimulation segment, while nascent, is projected to grow at a remarkable CAGR of 47.7% through 2034, reflecting early-stage research momentum and emerging therapeutic potential.
By Stimulation Site: The cervical spine segment led the market with an 85.9% share in 2025, underpinned by the high prevalence of cervical spinal cord injuries and clinical evidence supporting non-invasive cervical stimulation for upper-limb function recovery. The thoracic spine segment is expected to grow at a CAGR of 32.3%, reflecting broadening therapeutic applications across stimulation sites.
By Application: The spinal cord injury rehabilitation segment dominated in 2025 with a 48.9% share, driven by strong clinical emphasis on restoring upper-limb function and functional outcomes in SCI patients. The autonomic dysfunction management segment is projected to grow at the fastest application CAGR of 33.5%, as evidence builds for non-invasive SCS in managing cardiovascular and bladder autonomic dysfunction in SCI patients.
By End User: Hospitals dominated the market in 2025 and are projected to hold an 82.9% share in 2026, supported by growing SCI patient volumes, expanding healthcare infrastructure, and institutional procurement of approved devices. Specialty clinics are the fastest-growing end-user segment at a CAGR of 31.2%, reflecting increasing neurorehabilitation specialization and outpatient SCS program development.